GlaxoSmithKline and Vir start phase 2/3 study for Covid-19 antibody drug

Name: GlaxoSmithKline and Vir start phase 2/3 study for Covid-19 antibody drug
Uploaded: 2020-08-31T12:52:56.000Z
Duration: 1 min 52 s
Description: Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients who are at high risk of hospitalization. CNBC's Meg Tirrell reports.

Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients who are at high risk of hospitalization. CNBC's Meg Tirrell reports.

01:52

Mon, Aug 31 20208:52 AM EDT

Meg Tirrell